Accuray (NASDAQ:ARAY) Inc. is a global leader in precision radiation therapy for the treatment of cancer. The company designs, manufactures and sells advanced medical devices that deliver targeted, high-dose radiation with sub-millimeter accuracy. Its solutions are used by oncology centers, hospitals and academic research institutions to treat tumors in complex anatomical regions while minimizing exposure to surrounding healthy tissue.
The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform capable of non-invasive tumor removal; the TomoTherapy® System, which integrates computed tomography (CT) imaging with helical radiation delivery for adaptive and image-guided therapy; and the Radixact™ System, an evolution of TomoTherapy technology offering enhanced dose rates and real-time motion management. Accuray also provides software and service offerings such as Synchrony® real-time tumor tracking, treatment planning solutions and ongoing technical support to ensure optimal performance.
Founded in 1990 from research conducted at Stanford University, Accuray has its corporate headquarters in Madison, Wisconsin, and operates manufacturing facilities and service centers across North America, Europe and Asia. Over its history, the company has delivered thousands of treatment systems worldwide and collaborated with leading academic and clinical partners to advance the field of radiation oncology through ongoing research and development.
Accuray is led by President and Chief Executive Officer Joshua Levine, supported by a senior management team with extensive experience in medical technology, oncology and global operations. The company continues to expand its global footprint through strategic partnerships, clinical collaborations and investments in next-generation treatment solutions, reinforcing its commitment to improving patient outcomes and advancing cancer care.
